FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.

Related Keywords

, Reuters , Pharmaceuticals Inc Xforxolremdi , Why Avenue Therapeutics , Stock Is Falling , Rare Pediatric Disease Priority Review Voucher , Brookline Capital Markets , Going On With Sofi Technologies Stock ,